IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v15y2017i2d10.1007_s40258-016-0296-4.html
   My bibliography  Save this article

Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model

Author

Listed:
  • L. Gerlier

    (QuintilesIMS Real-World Evidence Solutions)

  • M. Lamotte

    (QuintilesIMS Real-World Evidence Solutions)

  • S. Grenèche

    (AstraZeneca)

  • X. Lenne

    (University Lille Nord de France)

  • F. Carrat

    (Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d’épidémiologie et de Santé Publique (IPLESP UMRS 1136)
    Saint-Antoine Hospital, APHP)

  • C. Weil-Olivier

    (University Paris VII)

  • O. Damm

    (Bielefeld University)

  • M. Schwehm

    (ExploSYS GmbH)

  • M. Eichner

    (University of Tübingen
    Epimos GmbH)

Abstract

Objectives We estimated the epidemiological and economic impact of extending the French influenza vaccination programme from at-risk/elderly (≥65 years) only to healthy children (2–17 years). Methods A deterministic, age-structured, dynamic transmission model was used to simulate the transmission of influenza in the French population, using the current vaccination coverage with trivalent inactivated vaccine (TIV) in at-risk/elderly individuals (current strategy) or gradually extending the vaccination to healthy children (aged 2–17 years) with intranasal, quadrivalent live-attenuated influenza vaccine (QLAIV) from current uptake up to 50% (evaluated strategy). Epidemiological, medical resource use and cost data were taken from international literature and country-specific information. The model was calibrated to the observed numbers of influenza-like illness visits/year. The 10-year number of symptomatic cases of confirmed influenza and direct medical costs (‘all-payer’) were calculated for the 0–17- (direct and indirect effects) and ≥18-year-old (indirect effect). The incremental cost-effectiveness ratio (ICER) was calculated for the total population, using a 4% discount rate/year. Results Assuming 2.3 million visits/year and 1960 deaths/year, the model calibration yielded an all-year average basic reproduction number (R 0) of 1.27. In the population aged 0–17 years, QLAIV prevented 865,000 influenza cases/year (58.4%), preventing 10-year direct medical expenses of €374 million. In those aged ≥18 years with unchanged TIV coverage, 1.2 million cases/year were averted (27.6%) via indirect effects (additionally prevented expenses, €457 million). On average, 613 influenza-related deaths were averted annually overall. The ICER was €18,001/life-year gained. The evaluated strategy had a 98% probability of being cost-effective at a €31,000/life-year gained threshold. Conclusions The model demonstrated strong direct and indirect benefits of protecting healthy children against influenza with QLAIV on public health and economic outcomes in France.

Suggested Citation

  • L. Gerlier & M. Lamotte & S. Grenèche & X. Lenne & F. Carrat & C. Weil-Olivier & O. Damm & M. Schwehm & M. Eichner, 2017. "Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 261-276, April.
    • Handle: RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-016-0296-4
    DOI: 10.1007/s40258-016-0296-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-016-0296-4
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40258-016-0296-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Yun-Kyung Kim & Joon Young Song & Hyeongap Jang & Tae Hyun Kim & Heejo Koo & Lijoy Varghese & Euna Han, 2018. "Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea," PharmacoEconomics, Springer, vol. 36(12), pages 1475-1490, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-016-0296-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.